yahoo_financeOriginal article
IDEAYA Biosciences Announces Successful FDA Type C Meeting for IDE849, DLL3 TOP1 ADC, on Phase 3 Registrational Trial Design for Potential Accelerated and Full Approval in Extensive Stage Small Cell Lung Cancer
RegulatoryIDE849Positive
AI Analysis
Summary
IDEAYA Biosciences announced a successful FDA Type C meeting for IDE849, a DLL3 TOP1 ADC, to discuss Phase 3 registrational trial design for potential accelerated and full approval in extensive stage small cell lung cancer.
Clinical Trial Data
Phase
Phase 3
Outcome Details
Successful FDA Type C Meeting for Phase 3 registrational trial design discussion
Importance:6/10
Sentiment:
0.70
FDA meetingType C meetingPhase 3small cell lung canceraccelerated approvalDLL3 TOP1 ADC
Related Companies
Read the original article
Published by yahoo_finance on August 31, 2026 10:00 AM